Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-α and be the cause of treatment related new onset disease: The need to measure circulating TNF-α

Journal of Rheumatology

Volumn 35, Issue 8, 2008, Pages 1679-

  Kast, Richard E ^a   Altschuler, Eric L ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; LETTER; MEASUREMENT; MONITORING; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; BIOMARKERS, PHARMACOLOGICAL; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49049098997     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. Song IH, Appel H, Haibel H, et al. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 2008;35:532-6. Epub 2008 Jan 15.
2. Kast RE. Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities - the role of bupropion. Leuk Res 2005;29:1459-63.
3. Bhatia A, Kast RE. Tumor necrosis factor (TNF) can paradoxically increase on etanercept treatment, occasionally contributing to TNF-mediated disease. J Rheumatol 2007;34:447-9; author reply 449-50.
4. Kanbe K, Inoue K, Inoue Y, Suzuki Y. Histological changes in bone marrow after treatment of infliximab for rheumatoid arthritis. Clin Rheumatol 2008;27:497-501. Epub 2007 Nov 27.
5. Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007;25:4542-9.
6. Kast RE. Aspirin, TNF-alpha, NFkB, and survival in multiple myeloma: the importance of measuring TNF-alpha. Inflammopharmacology 2006;14:256-9.
7. Kast RE. Aspirin use in myeloma: a note of caution regarding potential tumour necrosis factor-alpha elevation. Br J Haematol 2006;133:216.
8. Kim MS, Lee SH, Song MY, Yoo TH, Lee BK, Kim YS. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol 2007;374:1374-88.